Nonopioid analgesic pipeline: Pharmacology, safety, tolerability, and potential advantages over established agents

Techniques in Regional Anesthesia and Pain Management

Volumn 14, Issue 2, 2010, Pages 75-85

  Bal, Rajpreet ^a   Legree, Lakesha ^a   Diwan, Sudhir ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bupivicaine transermal patch; Capsaicin; Lacosamide; Milnacipran; Neuropathic pain; Pregabalin

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BUPIVACAINE; CAPSAICIN; CARBAMAZEPINE; CELECOXIB; DESIPRAMINE; DULOXETINE; FLUOXETINE; GABAPENTIN; HARKOSERIDE; IBUPROFEN; IMIPRAMINE; INDOMETACIN; LAMOTRIGINE; MILNACIPRAN; NEUROLEPTIC AGENT; OPIATE; PARACETAMOL; PLACEBO; PREGABALIN; ROFECOXIB; SAVELLA; TOPIRAMATE; UNCLASSIFIED DRUG; VALDECOXIB; VALPROIC ACID; VENLAFAXINE;

ABNORMAL VISION; ACUTE KIDNEY TUBULE NECROSIS; AGRANULOCYTOSIS; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANALGESIA; APLASTIC ANEMIA; ARTICLE; ATAXIA; ATRIOVENTRICULAR BLOCK; BLEEDING; BLOOD PRESSURE; BLURRED VISION; CHRONIC PAIN; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COCHRANE LIBRARY; COMA; COMPARATIVE STUDY; CONFUSION; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIPLOPIA; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPNEA; DYSURIA; ECONOMICS; EUPHORIA; FATIGUE; FIBROMYALGIA; FOCAL EPILEPSY; GASTROINTESTINAL DISEASE; GLAUCOMA; HEAD; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERSENSITIVITY; HYPERTENSION; HYPOGLYCEMIA; HYPONATREMIA; INJECTION SITE ERYTHEMA; INSOMNIA; IRRITABILITY; KIDNEY DISEASE; LIVER INJURY; LIVER TOXICITY; MANIA; MEDICAL LITERATURE; MEMORY DISORDER; MIGRAINE; MUSCULOSKELETAL PAIN; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUROPATHIC PAIN; NONHUMAN; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PANCREATITIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHYSICIAN; PIPELINE; POSTHERPETIC NEURALGIA; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RHABDOMYOLYSIS; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STROKE; STUPOR; SUDDEN DEATH; SYNCOPE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; TREMOR; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; URINE RETENTION; VERTIGO; VISUAL DISORDER; VOMITING; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 77953300739     PISSN: 1084208X     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.trap.2010.03.001     Document Type: Article

References (44)

1. Ropper A.H., et al. Pain. In: Ropper A.H., and Samuels M.A. (Eds). Adams and Victor's Principles of Neurology. (ed 9) (2009), McGraw-Hill, New York Chapter 8
2. Attal N., and Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand Suppl 173 (1999) 12-24 discussion 48-52
3. Fauci A., et al. Pain: Pathophysiology and management. In: Fauci A.S., Braunwald E., Kasper D.L., et al. (Eds). Harrison's Principles of internal medicine. (ed 17) (2008), McGraw-Hill, New York Chapter 12
4. Morgan G.E., et al. Pain management. In: Morgan G.E., Mikhail M.S., and Murray M.J. (Eds). Clinical Anesthesiology (2006), McGraw-Hill, New York Chapter 18
5. Kroenke K., Krebs E.E., and Bair M.J. Pharmacotherapy of chronic pain: A synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 31 (2009) 206-219
6. Sternbach R.A. Survey of pain in the United States: The Nuprin pain. Report. Clin J Pain 2 (1986) 49-53
7. Stewart W.F., Ricci J.A., Chee E., Morganstein D., and Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. J Am Med Assoc 290 (2003) 2443-2454
8. Tremon-Lukats I.W., Megeff C., and Backonja M.M. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 60 (2000) 1029-1052
9. Hyllested M., Jones S., Pedersen J.L., and Kehlet H. Comparative effect of paracetamol, NSAIDs, or their combination in post operative pain management: A qualitative review. Br J Anaesth 88 (2002) 199-214
10. Shaojun. Clinical use and pharmacologic properties of selective COX-2 inhibitor. Eur J Clin Pharmacol 64 (2008) 233-252
11. Pincus. Patient preference for placebo, acetaminophen (paracetamol) or celecoxib efficacy studies (PACES): Two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 63 (2004) 931-939
12. Katzung B.G., Masters S.B., and Trevor A.J. Drugs that act in the central nervous system, in Basic and Clinical Pharmacology. (ed 11) (2009), McGraw-Hill, New York Section 5
13. Campbell F.G., et al. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. J Neurosurg Neurol Psychiatry 29 (1966) 265-267
14. Killian J.M., and Fromm G.H. Carbamazepine in the treatment of neuralgia. Arch Neurol 19 (1968) 129-136
15. Rull J.A., Quibrera R., González-Millan H., et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: Double-blind crossover study. Diabetologia 5 (1969) 215-220
16. Nicol C. A four year double blind randomized study of Tegretol in facial pain. Headache 9 (1969) 54-57
17. McKellar G., and Singh G. Celecoxib in arthritis: Relative risk management profile and implications for patients. Ther Clin Risk Manag 5 (2009) 889-896
18. Wiffen. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 3 (2005) CD001133
19. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. J Am Med Assoc 280 (1998) 1831-1836
20. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the treatment of post-herpetic neuralgia: A randomized controlled trial. J Am Med Assoc 280 (1998) 1837-1842
21. Detrembleur C., De Nayer J., and van den Hecke A. Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis. A randomised, placebo, double-blind and cross-over trial. Osteoarthritis Cartilage 13 (2005) 206-210
22. Stern T.A., Rosenbaum J.F., Fava M., Biederman J., and Rauch S.L. Anticonvulsants, in Massachusetts General Hospital: Comprehensive Clinical Psychiatry. (ed 11) (2008), Mosby-Elsevier, Philadelphia
23. Bradley. Principles of pain management, in Neurology in Clinical Practice (2004), Elsevier, Philadelphia
24. Max M.B., Lynch S.A., and Muir J. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326 (1992) 1250-1256
25. Pfizer: Lyrica (pregabalin) capsules prescribing information. New York, June 2007
26. Dworkin R.H., Corbin A.E., Young J.P., et al. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 60 (2003) 1274-1283
27. Sabatowski R., Galvez R., Cherry D.A., et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain 109 (2004) 26-35
28. Crofford L.J., Mease P.J., Simpson S.L., et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136 (2008) 419-431
29. Lyseng-Williamson K.A., and Siddiqui M.A. Pregabalin: A review of its use in fibromyalgia. Drugs 68 (2008) 2205-2223
30. Pregabalin (Lyrica) for fibromyalgia. Med Lett Drugs Ther 49 (2007) 77-78
31. Arnold L.M., Russell I.J., Diri E.W., et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9 (2008) 792-805
32. Wymer J.P., Simpson J., Sen D., et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: An 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 25 (2009) 376-385
33. Wallace MS, Kudrow DB, McElveen WA, et al: Durect pharma: Clinical trial results: A randomized, double-blind, placebo-controlled, trial of three-day bupivicaine patch (Eladur) in patients with post herpetic neuralgia.
34. Chong Y.Y., and Ng B.Y. Clinical aspects and management of fibromyalgia syndrome. Ann Academy Med Singapore 38 (2009) 967-973
35. Chong Y.Y., and Ng B.Y. Clinical aspects and management of fibromyalgia syndrome. Ann Academy Med Singapore 38 (2009) 967-973
36. Perucca E. Marketed new antiepileptic drugs: Are they better than old-generation agents?. Ther Drug Monit 24 (2002) 74-80
37. Ben-Menachem E., et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48 (2007) 1308-1317
38. th Annual Meeting, 2008
39. Available at: http://www.durect.com/wt/durect/page_name/bupivacaine
40. Available at: http://www.anesiva.com/wt/page/adlea
41. Savella (milnacipran) package insert (March 2009), Forest, Pharmaceuticals, Inc, St. Louis, MO
42. Clauw D.J., Mease P., Palmer R.H., et al. Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 30 (2008) 1988-2004
43. Carville S.F., Arendt-Nielsen S., Bliddal H., et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 67 (2008) 536-541
44. Mease P.J., Clauw D.J., Gendreau R.M., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 36 (2009) 398-409